Noronha Vanita, Punatar Sachin, Joshi Amit, Desphande Rushi V, Prabhash Kumar
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
J Cancer Res Ther. 2016 Jan-Mar;12(1):6-11. doi: 10.4103/0973-1482.172575.
Sunitinib-induced thrombotic microangiopathy (TMA) is a secondary TMA caused by sunitinib. Despite the extensive use of sunitinib in patients with renal cell carcinoma and other malignancies, little is known about this complication of sunitinib. No clinical trials of sunitinib have studied this complication in any group of patients. We here review the normal physiology of vascular endothelial growth factor in the kidney, and discuss the pathogenesis, clinical and laboratory manifestations, pathological changes in the kidney, and the management of this uncommon complication of sunitinib.
舒尼替尼诱导的血栓性微血管病（TMA）是一种由舒尼替尼引起的继发性TMA。尽管舒尼替尼在肾细胞癌和其他恶性肿瘤患者中广泛使用，但对于舒尼替尼的这种并发症知之甚少。尚无舒尼替尼的临床试验对任何患者群体中的这种并发症进行研究。我们在此回顾肾脏中血管内皮生长因子的正常生理学，并讨论舒尼替尼这种罕见并发症的发病机制、临床和实验室表现、肾脏病理变化以及管理。
